Researchers from Monash University have made a crucial breakthrough that could pave the way for new treatments in cancer and neurological disorders. At the centre of their discovery is the protein LYCHOS, which has the unique ability to sense cholesterol levels and regulate cell growth. This research could transform how we approach diseases caused by abnormal cell growth.
Cholesterol, while vital to cellular health, can lead to problems if not properly regulated. Unchecked cholesterol levels are often linked to tumours and neurological issues. The Monash research team, led by Associate Professors Andrew Ellisdon and Michelle Halls, revealed the structure of LYCHOS for the first time, thanks to advanced cryo-electron microscopy. This cutting-edge technique allowed the team to capture a highly detailed image of the protein’s three-dimensional structure.
What makes LYCHOS truly remarkable is its unusual composition, which shares characteristics with both plant transporters and G protein-coupled receptors (GPCRs), a type of protein commonly targeted by pharmaceuticals. This dual nature of LYCHOS as a cholesterol sensor could have significant implications for drug development. The team believes that targeting LYCHOS could help control the unchecked cell growth that often leads to diseases like cancer.
LYCHOS is not just any protein—it plays a key role in activating mTORC1, a complex involved in regulating cell metabolism and growth. With mTORC1 implicated in many serious health conditions, LYCHOS represents a promising avenue for treatment development. Drugs aimed at modulating its activity could provide much-needed precision in tackling diseases driven by cholesterol imbalance.
The team’s work is already sparking excitement in the field of drug discovery. The discovery of LYCHOS’ hybrid structure, which combines a plant-like transporter and a GPCR, is unprecedented in human biology. This unusual combination allows LYCHOS to detect cholesterol and control cell growth in a way that has never been observed before.
By deepening their understanding of LYCHOS, researchers hope to develop targeted treatments for conditions like cancer and metabolic disorders. It’s not just a victory for the Monash team; this breakthrough could have far-reaching impacts on how we treat some of the most challenging diseases.
Support independent community journalism. Support The Indian Sun.
Follow The Indian Sun on X | Instagram | Facebook
Support Independent Community Journalism
Dear Reader,The Indian Sun exists for one reason: to tell stories that might otherwise go unheard.
We report on local councils, state politics, small businesses and cultural festivals. We focus on the Indian diaspora and the wider multicultural community with care, balance and accountability. We publish in print and online, send regular newsletters and produce video content. We also run media training programs to help community organisations share their own stories.
We operate independently.
Community journalism does not have the backing of large media corporations. Advertising revenue fluctuates. Platform algorithms change. Costs continue to rise. Yet the need for credible, grounded reporting in a multicultural Australia has never been greater.
When you support The Indian Sun, you support:
• Independent reporting on issues affecting migrant communities
• Coverage of local and state decisions that shape daily life
• A platform for small businesses and community groups
• Media training that builds skills within the community
• Journalism accountable to readers
We cannot cover everything, but we work to cover what matters.
If you value thoughtful reporting that reflects Australia’s diversity, we invite you to contribute. Every donation helps us maintain the quality and consistency of our work.
Please consider making a contribution today.
Thank you for your support.
The Indian Sun Team
